CAMP4 Therapeutics【CAMP】銘柄情報

CAMP4 Therapeutics Corporation (CAMP) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

4.45

( 5.45% )

買値

4.38

売値

4.44

出来高

7,428

4.22 日の範囲 4.46

1.305 52 週間の範囲 7.75

時価総額

231.07M

前日終値

4.22

始値

4.22

時刻

4.4174

最終取引時間

00:38:42

財務取引量

US$ 32,557

VWAP

4.383

平均取引量 (3 か月)

US$ 191,933

発行済株式数

51,925,800

配当利回り

PER

-1.9

1 株当たり利益 (EPS)

-2.17

歳入

3.93M

純利益

-86.3M

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also de... Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. 詳細を表示

セクター

業界

ウェブサイト

www.camp4tx.com

本社

Cambridge, United States

設立

2026

CAMP4 Therapeutics Corporation is listed in the sector of the ナスダック市場 with ticker CAMP. The last closing price for CAMP4 Therapeutics was US$4.22. Over the last year, CAMP4 Therapeutics shares have traded in a share price range of US$ 1.305 to US$ 7.75.

CAMP4 Therapeutics currently has 51,925,800 shares in issue. The market capitalisation of CAMP4 Therapeutics is US$231.07 million. CAMP4 Therapeutics has a price to earnings ratio (PE ratio) of -1.90.

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”...

Form 8-K - Current report

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory...

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.21	4.95283018868	4.24	4.735	3.99	89434	4.2012145	CS
4	0.11	2.53456221198	4.34	4.735	3.9	70667	4.24564611	CS
12	-0.66	-12.915851272	5.11	5.16	3.8	84829	4.42880788	CS
26	-1.44	-24.4482173175	5.89	7.75	3.3	168842	5.60711852	CS
52	2.79	168.072289157	1.66	7.75	1.305	308338	3.53056707	CS
156	2.45	122.5	2	12.3	0.1349	283597	2.16146034	CS
260	-9.5	-68.1003584229	13.95	14.44	0.1349	295333	3.71908217	CS